Key Takeaways
- Guggenheim Securities boosted its Eli Lilly price target from $1,235 to $1,273 while reaffirming a Buy rating
- Shares currently trade near $1,189, reflecting a 51% gain over the trailing twelve months
- The firm anticipates Q2 revenue reaching $20.66 billion, surpassing the $20.55 billion Street estimate
- Foundayo, the company’s oral weight-loss medication, is poised for accelerated sales growth following June’s consumer marketing push
- Success probability for pipeline candidate retatrutide increased to 85%, with projected peak sales of $25 billion by 2035
Guggenheim Securities analyst Seamus Fernandez upgraded his price objective for Eli Lilly shares to $1,273 from $1,235 this Monday while maintaining his Buy recommendation. The revised target represents approximately 7% upside from the stock’s current level around $1,189.
Shares of LLY have surged 51% during the past year, pushing the pharmaceutical behemoth’s market capitalization to approximately $1.06 trillion. The stock is hovering close to its 52-week peak of $1,249.
Fernandez refined his financial model in advance of Eli Lilly’s second-quarter results scheduled for August 5, incorporating updated prescription data and currency exchange rate projections. Guggenheim’s revised forecast calls for Q2 revenue of $20.66 billion, exceeding the consensus Wall Street estimate of $20.55 billion.
Domestic prescription volume for tirzepatide — marketed under the brand names Zepbound and Mounjaro — remains robust, forming the foundation for Guggenheim’s quarterly projections. The company has posted 47% year-over-year revenue expansion, generating $72.25 billion over the past twelve months.
Obesity Treatment Portfolio Captures Market Interest
Eli Lilly’s recently introduced obesity pill Foundayo entered the market in April, prompting Guggenheim to moderate its near-term revenue projections given the product’s early commercialization phase. The firm emphasized, however, that direct-to-consumer advertising campaigns only launched in full force during early June, suggesting meaningful sales acceleration lies ahead.
Guggenheim anticipates the Q2 conference call will emphasize guidance revisions, geographic market expansion initiatives, and potential Medicare reimbursement for the company’s obesity therapeutics portfolio.
Regarding pipeline developments, Guggenheim elevated its probability of regulatory approval for retatrutide — a next-generation obesity treatment candidate — from 70% to 85%. This adjustment follows clinical data unveiled at the American Diabetes Association scientific sessions. The analyst projects retatrutide could generate more than $25 billion in annual revenue by 2035.
Wall Street Consensus Remains Favorable
Guggenheim’s positive stance aligns with broader analyst sentiment. Truist Securities elevated its LLY price objective to $1,370, highlighting robust domestic prescription trends for Zepbound and Mounjaro. Cantor Fitzgerald adjusted its target upward to $1,350 alongside an Overweight rating.
RBC Capital preserved its Outperform designation with a $1,250 price objective, emphasizing favorable long-term growth prospects.
Among 22 sell-side analysts covering the stock, LLY commands a consensus Strong Buy rating, composed of 20 Buy recommendations and two Hold ratings issued within the past three months.
The mean price target across this cohort stands at $1,294.06, suggesting approximately 17% appreciation potential from present trading levels.
Eli Lilly is scheduled to deliver 16 research presentations at the 2026 Alzheimer’s Association International Conference in London, focusing on its Alzheimer’s therapy Kisunla and associated clinical outcomes.
The pharmaceutical company will release its second-quarter financial results on August 5.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
